Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis

  |  Issue: August 2021  |  

No new safety signals were observed in the analysis.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital. 

References

  1. Janssen Pharmaceutical Companies of Johnson & Johnson. News release: New phase 3 data showed first-in-class Tremfya (guselkumab) provided durable complete skin clearance through five years in moderate to severe plaque psoriasis (PsO) and robust joint symptom improvement through 52 weeks in active psoriatic arthritis (PsA). 2021 March 16.
  2. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p19-subunit of interleukin 23, through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis [abstract]. The Innovations in Dermatology: Virtual Spring Conference. 2021 Mar 16–20.

Related Articles

    The Heterogeneity of Psoriatic Arthritis

    SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.

    Guselkumab Promising in Patients with PsA

    Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi).

    Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

    A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…